atai Life Sciences / Beckley Psytech (ATAI) — The partners reported positive results from an open-label Phase 2a study of a two-dose induction regimen of BPL-003 (intranasal mebufotenin/5-MeO-DMT) in treatment-resistant depression.
Among 12 evaluable patients, a second dose drove a mean MADRS reduction of 19.0 points, with remission rising from 25% to 50% at Week 8 and effects sustained through Week 12. The data support a planned Phase 3 program expected to begin in the first half of 2026.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.